- Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes.
Methods: Individuals receiving either heterologous (ChAdOx1-S [AstraZeneca, Cambridge, UK]/BNT162b2 [Pfizer-BioNTech, Mainz, Germany]; n = 306) or homologous (messenger RNA [mRNA]-1273 [Moderna, Cambridge, Massachusetts, USA]; n = 139) vaccination were asked to participate when receiving their second dose. Reactogenicity was assessed after 1 month, immunogenicity after 1, 3, and/or 6 months, including a third dose, through SARS-CoV-2 antispike immunoglobulin G, surrogate virus neutralization test, and a plaque reduction neutralization test against the Delta (B.1.167.2) and Omicron (B.1.1.529; BA.1) variants of concern.
Results: The overall reactogenicity was lower after heterologous vaccination. In both cohorts, SARS-CoV-2 antispike immunoglobulin G concentrations waned over time with the heterologous vaccination demonstrating higher neutralizing activity than homologous mRNA vaccination after 3 months to low neutralizing levels in the Delta plaque reduction neutralization test after 6 months. At this point, 3.2% of the heterologous and 11.4% of the homologous cohort yielded low neutralizing activity against Omicron. After a third dose of an mRNA vaccine, ≥99% of vaccinees demonstrated positive neutralizing activity against Delta. Depending on the vaccination scheme and against Omicron, 60% to 87.5% of vaccinees demonstrated positive neutralizing activity.
Conclusion: ChAdOx1-S/BNT162b2 vaccination demonstrated an acceptable reactogenicity and immunogenicity profile. A third dose of an mRNA vaccine is necessary to maintain neutralizing activity against SARS-CoV-2. However, variants of concern-adapted versions of the vaccines would be desirable.
MetadatenVerfasserangaben: | Niko KohmerORCiDGND, Shivana Stein, Barbara SchenkGND, Katharina GrikscheitORCiD, Melinda MetzlerORCiD, Holger RabenauORCiDGND, Marek WideraORCiDGND, Eva HerrmannORCiDGND, Sabine WickerORCiDGND, Sandra CiesekORCiDGND |
---|
URN: | urn:nbn:de:hebis:30:3-787996 |
---|
DOI: | https://doi.org/10.1016/j.ijid.2022.12.034 |
---|
ISSN: | 1201-9712 |
---|
Titel des übergeordneten Werkes (Englisch): | International journal of infectious diseases |
---|
Verlag: | Elsevier |
---|
Verlagsort: | Amsterdam |
---|
Dokumentart: | Wissenschaftlicher Artikel |
---|
Sprache: | Englisch |
---|
Datum der Veröffentlichung (online): | 18.01.2023 |
---|
Datum der Erstveröffentlichung: | 23.12.2022 |
---|
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Datum der Freischaltung: | 13.11.2023 |
---|
Freies Schlagwort / Tag: | BNT162b2; ChAdOx1-S; Heterologous prime-boost; Immunogenicity; Reactogenicity |
---|
Jahrgang: | 128.2023 |
---|
Seitenzahl: | 10 |
---|
Erste Seite: | 166 |
---|
Letzte Seite: | 175 |
---|
HeBIS-PPN: | 516175513 |
---|
Institute: | Medizin |
---|
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Lizenz (Deutsch): | Creative Commons - CC BY-NC-ND - Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International |
---|